EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing

Tatiane Montella iD, Mariano Zalis, Mauro Zukin, Vladmir Claudio Cordeiro de Lima iD, Clarissa Baldotto iD, Pedro De Marchi iD, Paulo Salles iD, Clarissa Mathias, Carlos Barrios iD, Carolina Kawamura, Aknar Calabrich iD, Luiz Henrique Araújo iD und 5 weitere

JCO Global Oncology · 2023

DOI: 10.1200/go.22.00426 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JCO Global Oncology, 2023. Verfasst von Tatiane Montella und 16 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Oncoclínicas, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE There is a paucity of consistent data concerning genetic mutations in Brazilian patients with lung cancer. The aim of this study was to retrospectively analyze epidermal growth factor receptor (EGFR) mutations detected in a real-world scenario using a large cohort of Brazilian patients with non–small-cell lung cancer (NSCLC). MATERIALS AND METHODS This was a cross-sectional, observational, descriptive study on the basis of a database of EGFR molecular analysis from tumor samples of patients with a confirmatory histopathological diagnosis of primary lung cancer. Specimens were collected from 2013 to 2017 and were tested using cobas, next-generation sequencing, and Sanger sequencing platforms. RESULTS A total of 7,413 tumor specimens were tested. The patients were predominantly women with a median age of 67.0 years. Patients with at least one mutation represented 24.2% of the total sample. Among the positive patients, the majority had just one mutation, but two or more simultaneous mutations were observed in 1.52% of patients. Exon 19 deletion was the most prevalent alteration in the sample (12.8%), followed by exon 21 L858R (6.9%) and exon 20 insertion (1.6%). All others were considered uncommon mutations and were observed in 18.5% of all mutated patients and 4.0% of the total sample (2.3%-18.7% depending on the sequencing method). CONCLUSION This study examined the prevalence of EGFR mutations in Brazilian patients with NSCLC using different technologies, suggesting that the type of method used, directed or nondirected against specific mutations, influences the analysis, particularly for uncommon mutations, which will be missed by mutation-specific approaches such as cobas testing. Our estimates are the largest in Latin America and are consistent with previous reports from other parts of the world. Besides the variability in methods described here as technology incorporation advances in a nonhomogeneous manner, it is probably like the real-world clinical setting Brazilian oncologists face in their daily practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansFemaleAgedMaleRetrospective StudiesBrazilCross-Sectional StudiesMutationErbB ReceptorsMolecular Diagnostic Techniques

Substanzen

ErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Instituto Oncoclínicas, Rio de Janeiro, Brazil.
  • Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, Brazil.
  • AC Camargo Cancer Center, São Paulo, Brazil.
  • Instituto Mario Penna, Minas Gerais, Brazil.
  • DASA Oncologia, Rio de Janeiro, Brazil.
  • Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

ORCID-Profile: Tatiane Montella, Vladmir Claudio Cordeiro de Lima, Clarissa Baldotto, Pedro De Marchi, Paulo Salles, Carlos Barrios, Aknar Calabrich, Luiz Henrique Araújo, Gilberto Castro, Marcelo Reis, Carlos Gil Ferreira

Zitieren

APA

Montella, T., Zalis, M., Zukin, M., Cordeiro de Lima, V. C., Baldotto, C., De Marchi, P., Salles, P., Mathias, C., Barrios, C., Kawamura, C., Calabrich, A., Araújo, L. H., Castro, G., Bustamante, C., Santa Maria, A., Reis, M., & Ferreira, C. G. (2023). EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing. JCO Global Oncology. https://doi.org/10.1200/go.22.00426

Vancouver

Montella T, Zalis M, Zukin M, Cordeiro de Lima VC, Baldotto C, De Marchi P, et al. EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing. JCO Global Oncology. 2023. doi:10.1200/go.22.00426

BibTeX
@article{Montella2023,
  author = {Montella, Tatiane and Zalis, Mariano and Zukin, Mauro and Cordeiro de Lima, Vladmir Claudio and Baldotto, Clarissa and De Marchi, Pedro and Salles, Paulo and Mathias, Clarissa and Barrios, Carlos and Kawamura, Carolina and Calabrich, Aknar and Araújo, Luiz Henrique and Castro, Gilberto and Bustamante, Carolina and Santa Maria, André and Reis, Marcelo and Ferreira, Carlos Gil},
  title = {EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing},
  journal = {JCO Global Oncology},
  year = {2023},
  doi = {10.1200/go.22.00426}
}
Kostenlos starten →